
2026 iCARDIO Alliance Global Implementation Guidelines on Heart Failure

[10.4081/cardio.2026.117](#)

Declaration of Interest Report

Vijay Chopra (VC), William T. Abraham (WTA), Offer Amir (OA), Stefan D. Anker (SDA), John J. Atherton (JJA), Fernando Bacal (FB), Ralph Stephan von Bardeleben (RSvB), Dulce Brito (DB), Lucrecia Maria Burgos (LMB), Javed Butler (JB), Maria Rosa Costanzo (MRC), Albertino Damasceno (AD), Justin A. Ezekowitz (JAE), Ishaque Hameed (IH), Sivadasanpillai Harikrishnan (SH), Anuradha Lala (AL), Ileana L. Piña (ILP), Clara Saldarriaga (CS), David Sim (DS), John R. Teerlink (JRT), Nqoba Tsabedze (NT), Hiroyuki Tsutsui (HT), Jing Yu (JY), Yuhui Zhang (YZ), Mohammad Zubaid (MZ), Nikhil Balankhe (NB), John G.F. Cleland (JGFC), Gemma Figtree (GF1), Gerasimos Filippatos (GF2), Marat Fudim (MF), Habib Gamra (HG), Juan Esteban Gomez-Mesa (JEGM), Martha Gulati (MG), James L. Januzzi (JLJ), Marvin A. Konstam (MAK), JoAnn Lindenfeld (JL), Robert J. Mentz (RJM), Rhonda Monroe (RM), Elijah Ogola (EO), Fausto J. Pinto (FJP), Girish C. Rajadhyaksha (GCR), Carlos E. Ramos (CER), Giuseppe Rosano (GR), Victor Rossel (VR), Naoki Sato (NS), P. Christian Schulze (PCS), Andrew Sindone (AS), Kadhim Sulaiman (KS), Muthiah Vaduganathan (MV), Harriette G.C. Van Spall (HGCVS), Dirk J. van Veldhuisen (DJvV), Stephan von Haehling (SvH), Tzung-Dau Wang (TDW), Pepe Zamorano (PZ), Michael Böhm (MB), Andrew J.S. Coats (AJSC), Shelley Zieroth (SZ)

VC: in the past 36 months, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Pfizer, AstraZeneca, Novartis, Sun Pharma, Boehringer, Sanofi, NovoNordisk, Mankind, Lupin, Cipla, Torrent, Dr. Reddy's.

MSK: has received fees from Bayer and Novartis.

MA: in the past 36 months, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca, Boehringer Ingelheim, Novartis, Pfizer, Bayer.

WTA: in the past 36 months, grants or contracts from the National Institutes of Health (National

Heart, Lung, and Blood Institute); consulting fees from Abbott, AquaPass, Cordio, CVRx, Innoventric, Relief Cardiovascular, Sensible Medical, Vectorious, White Swell, Zoll Respicardia; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Impulse Dynamics; patents planned, issued or pending applicant: Ohio State Innovation Foundation; inventors: Emre Ertin and William T Abraham; Mobile Ultrawideband Radar for Monitoring Thoracic Fluid Levels and Cardio-Respiratory Function; Publication No. US2021/0290074 A1; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid for Heart Failure Collaboratory (HFC): Co-Chair Regulatory Policy and Implementation Science Working Group; Co-Chair HFC Academic Research Consortium Group; stock or stock options for scPharmaceuticals, V-Wave, scPharmaceuticals.

OA: in the past 36 months, consulting fees from Restore -Medical, SHL Telemedicine, Cordio-Medical; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Boehringer Ingelheim, Novartis; payment for expert testimony from Boehringer Ingelheim; participation on a Data Safety Monitoring Board or Advisory Board: NATIONAL PI IN MULTICENTER STUDIES/ STEERING COMMITTEE/ ADVISORY BOARD: REGENERON, NOVARTIS, Boehringer Ingelheim, DUKE UNIVERSITY GlaxoSmithKline Pharmaceuticals; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid for ESC CPC COMMITTEE, PRESIDENT NATIONAL CARDIOLOGY, ACC NATIONAL GOVERNORSHIP.

SDA: grants and personal fees from Vifor and Abbott Vascular, and personal fees for consultancies, trial committee work and/or lectures from Actimed, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Brahms, Cardiac Dimensions, Cardior, Cordio, CVRx, Cytokinetics, Edwards, Farraday Pharmaceuticals, GSK, HeartKinetics, Impulse Dynamics, Occlutech, Pfizer, Regeneron, Repairon, Scirent, Sensible Medical, Servier, Vectorious, and V-Wave. Named co-inventor of two patent applications regarding MR-proANP (DE 102007010834 & DE 102007022367), but he does not benefit personally from the related issued patents.

JJA: in the past 36 months, grants or contracts from Bayer: FINEARTS-HF National PI, Merck Sharp and Dohme: VICTOR-HF PI, Novo Nordisk: POSEIDON PI, Novo Nordisk: HERMES PI; consulting fees from Boehringer Ingelheim, Phebra, Sanofi-Genzyme, Seqirus, Viartis; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca, Bayer, Boehringer Ingelheim, Novo Nordisk, Astra Zeneca; support for attending meetings and/or travel from Bristol-Myers Squibb, Novo Nordisk, Viartis, Vifor Pharma; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid: Australian Government Medical Services Advisory Committee, National Cardiac Registry (NCR) Board Director: Cardiac Society of Australia and New Zealand (CSANZ) Representative.

FB: in the past 36 months, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Novartis, Bayer.

RSvB: in the past 36 months, grants or contracts from IZKS Göttingen Corelab; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events

from Abbott Vascular, JenaValve, Edwards Lifesciences, Philips, Medtronic, Siemens; Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid for Heart Valve Society USA (Board of Directors), EU SHD Coalition (Structural Heart and Gender Steering Committee).

DB: in the past 36 months, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca, Bayer, Bial, Pfizer; Support for attending meetings and/or travel from AstraZeneca, Bayer, Bial, Pfizer; Participation on a Data Safety Monitoring Board or Advisory Board for AstraZeneca, Advisory Board – Bayer, Advisory Board – Pfizer, Advisory Board – NovoNordisk; Receipt of equipment, materials, drugs, medical writing, gifts or other services from Medical writing support from Bayer, Medical writing support from Pfizer.

LMB: in the past 36 months, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca, Megalabs, Berkana, CSL Vifor, Temis Lotalo, Bayer; Support for attending meetings and/or travel from AstraZeneca.

JB: in the past 36 months, consulting fees from Abbott, Adaptix, American Regent, Amgen, AskBio, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardiac Dimension, Cardior, CSL Vifor, CVRx, Cytokinetics, Daxor, Diastol, Edwards, Element Sciences, Faraday, Idorsia, Impulse Dynamics, Imbria, Innolife, Intellia, Inventiva, Levator, Lexicon, Eli Lilly, Mankind, Medtronic, Merck, New Amsterdam, Novartis, NovoNordisk, Pfizer, Pharmacosmos, Pharmain, Prolaio, Pulnovo, Regeneron, Renibus, Reprieve, Roche, Rycarma, Saillant, Salamandra, Salubris, SC Pharma, SQ Innovation, Secretome, Sequanna, Transmural, TekkunLev, Tenex, Tricog, Ultronic, Vera, Zoll; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Boehringer Ingelheim-Lilly, Impulse Dynamics, Merck.

MRC: in the past 36 months, grants or contracts from Boehringer-Ingelheim, Bayer, Abbott (Steering Committee for GUIDE-HF); Consulting fees from Boehringer-Ingelheim, White Swell; Participation on a Data Safety Monitoring Board or Advisory Board for Merck; Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid for Nuwellis.

JA: during the conduct of the study, grants and personal fees from Amgen, Bayer, American Regent, Merck, Otsuka, Novo Nordisk, Applied Therapeutics, Cardurion, CSL-Vifor, AstraZeneca, BI-Lilly, US2.ai.

AL: in the past 36 months, grants or contracts from PCORI; consulting fees from Abiomed, Bayer, Cytokinetics, Cordio, AstraZeneca, Novo Nordisk, Tenax, Merck; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Zoll; Participation on a Data Safety Monitoring Board or Advisory Board for Sequana Medical.

CS: in the past 36 months, consulting fees from Bayer, Merck, Novo Nordisk; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca, Novartis, Eli Lilly, Boehringer Ingelheim, Servier, Pfizer, Sanofi, Bristol Mayer

Squibb, Amgen; support for attending meetings and/or travel from AstraZeneca, Boehringer Ingelheim.

JRT: in the past 36 months, grants or contracts from Amgen, AskBio, Astra Zeneca, Bayer, Boehringer-Ingelheim, Cardiac Dimensions, Cytokinetics, EBR Systems, Edwards, Endotronix, Impulse Dynamics, LivaNova, Medtronic, Myovant, PCORI, RECARDIO, Tectonic, V-Wave; consulting fees from AOP Medical, Astra Zeneca, Bayer, Boehringer-Ingelheim, Bristol Myers-Squibb, Cardiac Dimensions, Cytokinetics, Daiichi-Sankyo, EBR Systems, Edwards, Impulse Dynamics, Lilly, LivaNova, Medtronic, Myovant, Novartis, Pfizer, RECARDIO, ReCor Medical, Regeneron, Reprieve, Tectonic, Travere, V-Wave, ViCardia, Windtree Therapeutics; Participation on a Data Safety Monitoring Board or Advisory Board for Medtronic, Angitia, Cardurion, Merck KGaA, Kaiser Permanente, Edgewise Therapeutics; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid: for Heart Failure Society of America.

NT: in the past 36 months, grants or contracts from NovoNordisk; consulting fees from NovoNordisk; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from NovoNordisk, MERCK, Novartis, SERVIER, Pfizer, Sandoz, AstraZeneca, Boehringer-Ingelheim; support for attending meetings and/or travel from SERVIER, MERCK; participation on a Data Safety Monitoring Board or Advisory Board for NovoNordisk.

HT: in the past 36 months, consulting fees from Ono; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Otsuka; participation on a Data Safety Monitoring Board or Advisory Board for NovoNordisk.

NB: in the past 36 months, leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid for Chairman, Association of Physicians of India, Vidarbha Chapter.

JEGM: in the past 36 months, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca, Boehringer Ingelheim, Merck, Novartis, Sanofi, Pfizer.

JLJ: in the past 36 months, grants or contracts from Abbott Diagnostics, Applied Therapeutics, AstraZeneca, BMS, HeartFlow, and Novartis; consulting fees from Abbott, AstraZeneca, Beckman-Coulter, Boehringer-Ingelheim, Bristol-Myers, Intellia, Jana Care, Novartis, Pfizer, Merck, Roche Diagnostics, Siemens; participation on a Data Safety Monitoring Board or Advisory Board for Abbott, Abbvie, AstraZeneca, Bayer, CVRx, Pfizer, Roche Diagnostics, Takeda; Stock or stock options for Imbria Pharmaceuticals, Fibrosys, and Jana Care.

MAK: in the past 36 months, consulting fees from Imbria Pharmaceuticals, Fibrosys, Jana Care; participation on a Data Safety Monitoring Board or Advisory Board for Boehringer Ingelheim, Alnylam; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid for Cardiovascular Clinical Sciences.

RM: in the past 36 months, grants or contracts from PCORI, NIH; consulting fees from Novartis, Roche, Abiomed, V-Wave, Boehringer Ingelheim; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from San Diego Heart Failure Symposium, Abiomed, Med Ed/Medtronic, 4teen4, STRONG-HF; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid for RECHARGE Trial.

MCP: in the past 36 months, grants or contracts from Boehringer Ingelheim, Roche, SQ Innovations, AstraZeneca, Novartis, Novo Nordisk, Medtronic, Boston Scientific, Pharmacosmos; consulting fees from Abbott, Abbvie, Akero, Applied Therapeutics, Amgen, AnaCardio, Biosensors, Boehringer Ingelheim, Corteria, Novartis, AstraZeneca, Novo Nordisk, Abbvie, Bayer, Horizon Therapeutics, Foundry, Takeda, Cardiorentis, Pharmacosmos, Siemens, Eli Lilly, Vifor, New Amsterdam, Moderna, Teikoku, LIB Therapeutics, 3R Lifesciences, Reprieve, FIRE 1, Corvia, Regeneron; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Abbott, Abbvie, Akero, Applied Therapeutics, Amgen, Boehringer Ingelheim, Corteria, Novartis, AstraZeneca, Novo Nordisk, Abbvie, Bayer, Foundry, Takeda, Pharmacosmos, Eli Lilly, Vifor, 3R Lifesciences, Reprieve, FIRE 1, Corvia; participation on a Data Safety Monitoring Board or Advisory Board for AstraZeneca, Moderna, Teikoku; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid for Heart Failure Association of ESC.

FJP: in the past 36 months, consulting fees from Boehringer Ingelheim, Daichi Sankyo, Novartis, Servier, Vifor; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Boehringer Ingelheim, Daichi Sankyo, Novartis, Servier, Vifor, Zydus; participation on a Data Safety Monitoring Board or Advisory Board for Medtronic, Novartis, Servier, Vifor; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid for Immediate Past-President, World Heart Federation (WHF), Past-President, European Society of Cardiology (ESC).

AR: in the past 36 months, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca, Boehringer Ingelheim.

VR: in the past 36 months, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from TECNOFARMA, AXON-PHARMA, BOEHRINGER-INGELHEIM.

NS: in the past 36 months, consulting fees from Bayer, Terumo, Heart-lab; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Novartis, Roche, Heart organization, Abiomed, Boehringer-Ingelheim.

PCS: in the past 36 months, grants or contracts from German Research Foundation, German Heart Foundation, Boehringer Ingelheim Inc., Abiomed, Edwards; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Lilly, Bayer, AstraZeneca, Daiichi Sankyo, Novartis, Actelion, Roche, Sanofi Aventis, Pharmacosmos, Cytokinetics, Edwards, Medtronic, Thoratec, Boehringer Ingelheim, Heartware, Coronus, Abbott, Boston Scientific, St. Jude Medical, Abiomed, German Cardiac Society; support for attending meetings and/or travel from Bayer, Novartis, Actelion, Roche, Sanofi Aventis, Medtronic,

Thoratec, Heartware, Abbott, Pharmacosmos, Abiomed, Boehringer Ingelheim, Daiichi Sankyo, AstraZeneca, Cytokinetics, Edwards, Boston Sci., DGK, ESC; participation on a Data Safety Monitoring Board or Advisory Board for Lilly, Bayer, AstraZeneca, Daiichi Sankyo, Novartis, Actelion, Pharmacosmos, Cytokinetics, Edwards, Medtronic, Thoratec, Boehringer Ingelheim, Heartware, Coronus, Abbott, Boston Scientific, St. Jude Medical, Abiomed; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid for DGK, ACC, AHA, ISHLT, GIMED.

AS: in the past 36 months, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CSL, Edwards, Eli Lilly, Glaxo Smith Kline, HealthEd, Inside Practice, Menarini, Merck Sharp and Dohm, Moderna, Mylan, National Cardiac Monitoring Incorporated, Novartis, Novo Nordisk, Otsuka, Pfizer, Roche, Sanofi, Servier, Viatris, Vifor; support for attending meetings and/or travel from Pharmacosmos, Vifor, AstraZeneca, Boehringer Ingelheim, Novartis; participation on a Data Safety Monitoring Board or Advisory Board for Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CSL, Edwards, Eli Lilly, Glaxo Smith Kline, HealthEd, Inside Practice, Menarini, Merck Sharp and Dohm, Moderna, Mylan, National Cardiac Monitoring Incorporated, Novartis, Novo Nordisk, Otsuka, Pfizer, Roche, Sanofi, Servier, Viatris, Vifor; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid for Writing Committee for Cardiac Society/National Heart Foundation Guidelines for the Management of Heart Failure in Australia; stock or stock options for National Cardiac Monitoring Incorporated, National Cardiac Monitoring Australia Pty Ltd.; receipt of equipment, materials, drugs, medical writing, gifts or other services from Novartis, CSL, Vifor, Mylan, Roche.

HNS: in the past 36 months, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Novartis, AstraZeneca, Servier, Abbott, Bayer, Vifor.

HGCVS: in the past 36 months, grants or contracts from Medtronic, Bayer, Novo Nordisk, 4Teen4, Pfizer, Boehringer Ingelheim.

ASt: in the past 36 months, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Bayer, Servier, Roche; participation on a Data Safety Monitoring Board or Advisory Board for Servier - Patient Advisory Board 2024/2025.

LWS: in the past 36 months, grants or contracts from research support Endotronix/Edwards LifeSciences; participation on a Data Safety Monitoring Board or Advisory Board for DSMB – Livanova.

AJSC: In the past 36 months, consulting fees from Astra Zeneca, Bayer, Boehringer Ingelheim, Daiichi-Sankyo, Eli Lilly, GSK, Novartis, Novo Nordisk, Servier, Vifor, Actimed, Cardiac Dimensions, Corvia, ESN Cleer, Impulse Dynamics, Zoll; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Viatris, Pulnovo; participation on a Data Safety Monitoring Board or Advisory Board for Impulse Dynamics.

SZ: In the past 36 months, grants or contracts from AstraZeneca, Salubris Bio, Boehringer Ingelheim, Merck, Novartis, Pfizer; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Abbott, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Cytokinetics, Edwards, Eli Lilly, GSK, Medtronic, Merck, Novartis, Novo Nordisk, Pfizer, Vifor Pharma, Not for Profit Canadian Medical and Surgical KT Group, CCS, CHFS, Charite, EOCl, Liv, Medscape, Ology, PACE- CME, Radcliffe, Reach MD, Translational Medicine Academy.

GF1: In the past 36 months, grants or contracts from National Health and Medical Research Council, Australia; consulting fees from Bitterroot Bio, Novo Nordisk; payment or honoraria from Amgen, Novartis, CSL; patents planned, issued or pending applicant: US9638699B2 (Awarded)-biomarker, PCT/AU2021903786 (Provisional)- Novel P27X7 receptor antagonists, PCT/AU2021900465 (Provisional) – methods of wound healing, PCT/AU2018/050905 (Provisional)- P2X7 receptor methods; Participation on a Data Safety Monitoring Board or Advisory Board: Novo Nordisk, Colcardia; Leadership or fiduciary role in other board, society, committee or advocacy group: Chief Scientific Officer, CAD Frontiers; Director (Honorary), Australian Cardiovascular Alliance; Founder and shareholder- Prokardia Pty Ltd, Founder and shareholder- Kardiomics Pty Ltd

RJM: In the past 36 months research support from Abbott, Abiomed, Alleviant Medical, American Regent, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, CVRx, Cytokinetics, Daiichi Sankyo, Edwards, Eli Lilly, Endotronix, Lexicon, Medtronic, Merck, Novartis, Novo Nordisk, Otsuka, Pfizer, Pharmacosmos, Reprieve Cardiovascular, Respicardia, Roche, Rocket Pharmaceuticals, SQ Innovation, Vifor, Windtree Therapeutics, and Zoll; honoraria from Abbott, Abiomed, Alleviant Medical, American Regent, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, CVRx, Cytokinetics, Daiichi Sankyo, Edwards, Eli Lilly, Endotronix, Lexicon, Medtronic, Merck, Novartis, Novo Nordisk, Otsuka, Pfizer, Pharmacosmos, Reprieve Cardiovascular, Respicardia, Roche, Rocket Pharmaceuticals, SQ Innovation, Vifor, Windtree Therapeutics, and Zoll; Participation on a Data Safety Monitoring Board for REPRIEVE, CVRx and Windtree and Momentum Research.

PZ: In the past 36 months payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Bayer, Amgen, Novartis, Viatrix.

MB: consulting fees, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events and support for attending meetings and/or travel from Abbott, Amgen, Astra Zeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Edwards, Medtronic, Novartis, Pharmacosmos, Recor, Servier, and Vifor; participation on a Data Safety Monitoring Board or Advisory Board for Astra Zeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Edwards, Glaxo, Medtronic, Novartis, Pharmacosmos, Recor, Servier, and Vifor.

MF: Grants or contracts from the NIH, American College of Cardiology, Alleviant, Boehringer Ingelheim, Gradient, Novo Nordisk, Reprieve, Sardocor, Tenax, and Doris Duke; consulting fees from Abbott, Acorai, Ajax, Alio Health, Alleviant, Artha, Astellas, Audicor, AxonTherapies, Berlin Heals, Bioventrix, BMS, Bodyguide, Boehringer Ingelheim, Bodyport, Boston Scientific, Broadview, Cadence, Cardiosense, Cardioflow, Corstasis, Clinical Accelerator, CVRx, Daxor, Edwards LifeSciences, Echosens, Esperion, Feldschuh Foundation, Fire1, FlowMod, FutureCardia, Gradient, Hatteras, HemodynamiQ, Impulse Dynamics, ISHI, Lumia Health, Madera, Medtronic, Novo Nordisk, NucleusRx, Omega, Orchestra, Paragate, Parasym, Pharmacosmos, Privebio, Procyreon, Proton Intelligence, Puzzle, ReCor, Scirent, SCPharma, Shifamed, Splendo, Summacor, SutroSam, SyMap, Tenax, Terumo, Tricav, Vifor Pharma, Unorthodox, Vasa, Vironix, Viscardia, VizAI, Zoll.

JGFC: In the past 36 months Grants or contracts from Pharmacosmos; Consulting fees from Abbott, Bayer, CSL-Vifor, InnovaMed Sphere, Pharmacosmos; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from BIAL, Pharmanord; Payment for expert testimony from Bristow's; Participation on a Data Safety Monitoring Board or Advisory Board for CMR-GUIDE, RAF; Stock or stock options: Heartfelt Ltd, Vicardia.

MV: has received research grant support, served on advisory boards, or had speaker engagements with Alnylam Pharmaceuticals, American Regent, Amgen, AstraZeneca, Bayer AG, Baxter Healthcare, BMS, Boehringer Ingelheim, Chiesi, Cytokinetics, Esperion, Fresenius Medical Care, Idorsia Pharmaceuticals, Lexicon Pharmaceuticals, Merck, Milestone Pharmaceuticals, Novartis, Novo Nordisk, Pharmacosmos, Recordati, Relypsa, Roche Diagnostics, Sanofi, and Tricog Health, and participates on clinical trial committees for studies sponsored by Amgen, AstraZeneca, Bayer AG, Boehringer Ingelheim, Galmed, Impulse Dynamics, Novartis, Occlutech, and Pharmacosmos.

AD, IH, SH, TJ, ILP, DS, JY, YZ, MZ, EO, VP, GCR, CER, KS, TDW, DJvV: report no conflicts of interest.